Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study

Author:

Girard Nicolas,Bar Jair,Garrido Pilar,Garassino Marina C.,McDonald Fiona,Mornex Françoise,Filippi Andrea R.,Smit Hans J.M.,Peters Solange,Field John K.,Christoph Daniel C.,Sibille Anne,Fietkau Rainer,Haakensen Vilde D.,Chouaid Christos,Markman Ben,Hiltermann T. Jeroen N.,Taus Alvaro,Sawyer William,Allen Allison,Chander Pratibha,Licour Muriel,Solomon Benjamin

Funder

AstraZeneca

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference48 articles.

1. Royal College of Physicians. NLCA annual report (for the 2018 audit period), version 2. https://www.rcplondon.ac.uk/projects/outputs/annual-report-version-2-published-march-2021. Accessed January 28, 2022.

2. Analysis of stage and clinical/prognostic factors for lung cancer from SEER registries: AJCC staging and collaborative stage data collection system;Chen;Cancer,2014

3. Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004–2007;Walters;Thorax,2013

4. Therapeutic management options for stage III non-small cell lung cancer;Yoon;World J Clin Oncol,2017

5. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer;Aupérin;J Clin Oncol,2010

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3